Compare KRNY & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | CYBN |
|---|---|---|
| Founded | 1884 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.5M | 416.1M |
| IPO Year | 2005 | N/A |
| Metric | KRNY | CYBN |
|---|---|---|
| Price | $7.63 | $8.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.00 | ★ $74.50 |
| AVG Volume (30 Days) | 435.5K | ★ 916.5K |
| Earning Date | 01-29-2026 | 02-10-2026 |
| Dividend Yield | ★ 5.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $158,298,000.00 | N/A |
| Revenue This Year | $9.70 | N/A |
| Revenue Next Year | $15.22 | N/A |
| P/E Ratio | $16.13 | ★ N/A |
| Revenue Growth | ★ 23.27 | N/A |
| 52 Week Low | $5.45 | $4.81 |
| 52 Week High | $7.95 | $10.73 |
| Indicator | KRNY | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 68.97 |
| Support Level | $7.26 | $7.85 |
| Resistance Level | $7.56 | $9.12 |
| Average True Range (ATR) | 0.16 | 0.51 |
| MACD | -0.04 | 0.15 |
| Stochastic Oscillator | 57.89 | 68.59 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.